ANANDA Scientific and the David Geffen School of Medicine UCLA Announce a Clinical Trial Utilizing Liquid StructureTM Cannabidiol (CBD) for the Treatment of Opioid Use Disorder (OUD).

Lyotropic Delivery Systems Ltd. (LDS) in collaboration with American Ananda Scientific Inc. today announced the commencement of a clinical trial to be done in collaboration with the Jane and Terry Semel Institute at David Geffen School of Medicine at UCLA, to evaluate NantheiaTM ATL5, an investigational drug using cannabidiol (CBD). The product is aimed to treat Opioid Use Disorder, is based on new Liquid Delivery Structure Technology licensed from Lyotropic Delivery Systems (LDS) Ltd. in Jerusalem, Israel). The product enhances the effectiveness and stability of CBD. This innovation creates new potential for CBD therapeutics, in areas such as facilitating voluntary opioid sparing and the ability to reduce opioid intake in patients being treated or addicted to opioids.